Εκπαιδευτικά
Λίστα αντικειμένων
This article was authored and presented by Prof. Spyridonidis.
Participants: Dr. Liga, Dr. Tsokanas, Dr. Valera
Duration: 40mins
In this registry-based study which includes acute myeloid leukemia patients who underwent a matched unrelated donor allogeneic peripheral-blood stem cell transplantation in complete remission and...
Participants: Dr Liga, Dr Tsokanas, Dr Valera, Zoi Panagi (Pharmassist)
Presenter: Prof. Spyridonidis
Duration: 40 mins
Therapeutic options for patients with AML relapsing after allogeneic HCT range from chemotherapy or hypomethylating agents
with or without donor lymphocyte infusions to a 2nd allogeneic HCT. Available...
https://mds-risk-model.com/ by The International Working Group for the Prognosis of MDS - Bernard et al. NEJM Evidence 2022
Schematic guidelines for CRS and iTTP management were presented and discussed
Presenter: Prof Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Valera, Zoi Panagi (Pharmassist)
Germ-line missense mutations in PTPN11, the gene coding SHP-2, have been discovered as a major molecular event underlying Noonan syndrome, an autosomal dominant trait characterized by short stature, dysmorphic facies, and congenital heart defects, as well as in other closely related
developmental disorders....
THE EBMT acitivity in the COVIDera has ebnn published and discussed
Presenter A Spyridonidis
Part: ML, DT, CL, ES, NC
Novel approaches for the treatment of ALL in adults were discussed.
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Valera
Duration: 30 mins
We discussed about copper deficiency in myelodysplastic syndrome (MDS) patients
Presenter: Prof Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Valera
Duration: 40 mins
The combination of venetoclax and gilteritinib is a highly active and tolerable oral combination regimen that potentially improves
response frequency and depth over existing standards in a high-risk, mutation-defined group of patients with AML.
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr...
We discussed about preliminary analysis of the prospective, multicenter, phase III NEUTRODIET trial, which is studying the effects of diet on infection rates during neutropenia in patients undergoing autologous (auto)- or allogeneic (allo)‑HSCT. Data presented at EHA2022
Presenter: Prof. Spyridonidis
Participants: Dr. Liga,...
The new molecular m-IPSS is presented
Presenter Prof. Spyridonidis
Participants Dr. Liga, Dr Tsokanas, Dr. Valera Duration: 30 mins
Integrating Morphological, Clinical, and Genomic Data
2022 ELN
International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data
5th WHO
Presenter: Prof. Spyridonidis
Participants: Dr. Liga, Dr Tsokanas, Dr. Valera
Duration: 30 mins
Efficacy and safety of 10-day DEC followed by allografting to IC followed by allografting in older fit AML patients was discussed.
Presenter: Prof. Spyridonidis
Participants: Dr. Tsokanas, Dr. Liga, Dr. Valera
Duration: 30 mins
2022 European Leukemia Net (ELN) Recommendations for AML were discussed.
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Valera
Duration: 45 mins
Randomized study showing better pfs in mm patients treated with triple therapy and upfront autologous hct vs no hct
Presenter: Prof. Spyridonidis
Participants: Dr. Liga, Dr Tsokanas, Dr. Valera
https://www.nejm.org/doi/full/10.1056/NEJMoa2204925
We presented the new molecular International Prognostic Scoring System of MDS
Presenter: Prof. Spyridonidis
Participants: Dr.Liga, Dr. Tsokanas, Dr. Valera Dr. Verigou Dr. Lyssandrou
Keypoints
t-AML, sAML, AML-MRC can be nowadays clinically, morphologically and genetically (cytogenetics, somatic mut) identified
In these pts (most > 60 y of age) CPX-351 enables efficient and safe delivery of intensive chemotherapy
Consolidation with HCT in these pts is curative with real...
4o Eκπαιδευτικό Σεμινάριο στη Μεταμόσχευση Μυελού των Οστών: Πως ενσωματώνονται οι θεραπείες στόχευσης, η ανοσοθεραπεία και οι κυτταρικές θεραπείες στον σύγχρονο θεραπευτικό αλγόριθμο.
Επισυνάπτεται η ομιλία της Λίγκα Μαρία Ιατρού Αιματολόγου της ΜΜΜΟ ΠΓΝΠ με τίτλο "Επιλογή δότη στην απλοταυτόσημη μεταμόσχευση"
Παρουσιαστής:...
4o Eκπαιδευτικό Σεμινάριο στη Μεταμόσχευση Μυελού των Οστών: Πως ενσωματώνονται οι θεραπείες στόχευσης, η ανοσοθεραπεία και οι κυτταρικές θεραπείες στον σύγχρονο θεραπευτικό αλγόριθμο.
Επισυνάπτεται η ομιλία του Τσοκάνα Δημητρίου, Ιατρού Αιματολόγου της ΜΜΜΟ ΠΓΝΠ με τίτλο "Επαναπροσδιορίζοντας τις θεραπείες επιλογής, βελτιώνοντας...